Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

62 results about "Purine Antimetabolite" patented technology

An antimetabolite is a chemical that inhibits the use of a metabolite, which is another chemical that is part of normal metabolism. Such substances are often similar in structure to the metabolite that they interfere with, such as the antifolates that interfere with the use of folic acid.

Novel Concomitant Use of Sulfonamide Compound with Anti-Cancer Agent

The present invention relates to a pharmaceutical composition, a kit, a method of treating cancer and / or a method of inhibiting angiogenesis comprising a sulfonamide compound in combination with a platinum complex, a DNA-topoisomerase I inhibitor, an antimetabolite, a microtubule inhibitor or an antibiotic.
Owner:EISIA R&D MANAGEMENT CO LTD

Use of antitumor indolopyrrolocarbazole derivative and other anticancer agent in combination

This invention relates to a combined preparation for simultaneous, separate, or sequential administration in the treatment of cancer, comprising two separate preparations: a preparation comprising, in combination with a pharmaceutically acceptable carrier or diluent, at least one compound of general formula I: wherein R1 and R2 each independently represent a hydrogen atom, lower alkyl, or the like, and G represents pentosyl or the like, X1 and X2 each independently represent a hydrogen atom, a halogen atom, or the like or a pharmaceutically acceptable salt thereof; and a preparation, in combination with a pharmaceutically acceptable carrier or diluent, such as antitumor alkylating agents, antitumor antimetabolites, antitumor antibiotics, or plant-derived antitumor agents (a preparation comprising at least one compound of general formula I or a pharmaceutically acceptable salt thereof may be combined with two or more other antitumor agents), and a method for cancer treatment comprising the administration of these preparations in combination.
Owner:BANYU PHARMA CO LTD

High molecular weight derivative of nucleic acid antimetabolite

[Problems] A derivative of a nucleic acid antimetabolite is demanded which can show a higher therapeutic effect at a lower dose.[Means for Solving Problems] Disclosed is a high molecular weight derivative a nucleic acid antimetabolite, which is characterized by comprising a high molecular weight compound comprising a polyethylene glycol moiety and a polymer moiety having a carboxyl group in a side chain and a nucleoside derivative which can act as a nucleic acid antimetabolite, wherein the nucleoside derivative is bound to the carboxyl group in the side chain of the high molecular weight compound via a highly hydrophobic linker.
Owner:NIPPON KAYAKU CO LTD

Application of 2-bromide-isovanillin for the manufacture of a medicament for anti-cancer or/and radiation/chemotherapy sensitization

Use of 2-bromo-isovanillin in the preparation of an anticancer medicament and / or radio- and chemotherapy sensitizing medicament is disclosed. The medicament for the treatment of cancers and / or for radio- and chemotherapy sensitization comprising 2-bromo-isovanillin as active ingredient provided herein has the following features: (1) low toxicity, without evident adverse effects; (2) significant therapeutic effect, with remarkable proliferation inhibiting and pro-apoptotic effects in tumor cells; (3) a broad-spectrum anticancer activity; (4) suitable to be used in combination with antimetabolites, to enhance the effects and meanwhile lower the toxicity, and also to reduce multi-drug resistance; (5) convenient and safe administration, the main route being oral.
Owner:INST OF RADIATION MEDICINE ACAD OF MILITARY MEDICAL SCI OF THE PLA

Therapeutic agents for pancreatic cancer

We achieved the present invention on the basis of the finding that an excellent therapeutic effect against pancreatic cancer can be obtained by administering an XL-6 inhibitor and an antimetabolite to pancreatic cancer patients. We also found that metastatic lesions from human pancreatic cancer can be reduced and ascites can be eliminated.
Owner:NAT CANCER CENT +1

Therapeutic agents for pancreatic cancer

We achieved the present invention on the basis of the finding that an excellent therapeutic effect against pancreatic cancer can be obtained by administering an IL-6 inhibitor and an antimetabolite to pancreatic cancer patients. We also found that metastatic lesions from human pancreatic cancer can be reduced and ascites can be eliminated.
Owner:NAT CANCER CENT +1

Combination cancer therapy with an hsp90 inhibitor and an antimetabolite

InactiveUS20140296176A1Increasing side effect profileSurprising biological activityBiocideCarbohydrate active ingredientsCytarabineHsp Inhibitor
The invention provides a method of treating a subject with cancer, particularly leukemia, lymphoma, solid cancer such as colorectal cancer, gastric cancer, bladder cancer, non-small cell lung cancer, and breast cancer, comprising administering to the subject a compound of formulae (I) 40 or (Ia) in combination with an antimetabolite such as methotrexate, pemetrexed, cytarabine or nelarabine, or 5-fluorouracil, or capecitabine or their derivatives.
Owner:SYNTA PHARMA CORP

Agents for intravitreal administration to treat or prevent disorders of the eye

Methods and preparatons for treating disorders of the eye and / or causing posterior vitreous disconnection or disinsertion. Preparations containing a) urea, b) urea derivatives (e.g., hydroxyurea, thiourea), c) a non-steroidal anti-inflamatory agents, d) antmetabolites, e) urea, urea derivatives, non-enzymatic proteins, nucleosides, nucleotides and their derivatives (e.g., adenine, adenosine, cytosine, cytadine, guanine, guanitadine, guanidinium, thymidine, thimitadine, uradine, uracil, cystine), uric acid, calcium acetal salicylate, ammonium sulfate or other compound capable of causing non-enzymatic dissolution of the hyaloid membrane or e) any of the possible combinations thereof, are administered to the eye in therapeutically effective amounts.
Owner:KATO PHARMA

9h-pyrimido[4,5-b]indoles, 9h-pyrido[4',3':4,5]pyrrolo[2,3-d]pyridines, and 9h 1,3,6,9 tetraaza-fluorenes as chk1 kinase function inhibitors

The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain tricyclic compounds (referred to herein as TC compounds), and especially certain 9H-pyrimido[4,5-b]indole, 9H-pyrido[4′,3′:4,5]pyrrolo[2,3-d]pyridine, and 9H-1,3,6,9-tetraaza-fluorene compounds, which, inter alia, inhibit Checkpoint Kinase 1 (CHK1) kinase function. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit CHK1 kinase function, and in the treatment of diseases and conditions that are mediated by CHK1, that are ameliorated by the inhibition of CHK1 kinase function, etc., including proliferative conditions such as cancer, etc., optionally in combination with another agent, for example, (a) a DNA topoisomerase I or II inhibitor; (b) a DNA damaging agent; (c) an antimetabolite or TS inhibitor; (d) a microtubule targeted agent; and (e) ionising radiation.
Owner:CANCER RES TECH LTD

Therapeutic Oxy-Phenyl-Aryl Compounds and Their Use

ActiveUS20110201592A1Reducing and eliminating damaging effectBiocideOrganic chemistryDiseaseIn vivo
The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain oxy phenyl aryl compounds (referred to herein as OPA compounds), as described herein, which, inter alia, inhibit Checkpoint Kinase 2 (CHK2) kinase function. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit CHK2 kinase function, and in the treatment of diseases and conditions that are mediated by CHK2, that are ameliorated by the inhibition of CHK2 kinase function, etc., including proliferative conditions such as cancer, etc., optionally in combination with another agent, for example, (a) a DNA topoisomerase I or II inhibitor; (b) a DNA damaging agent; (c) an antimetabolite or TS inhibitor; (d) a microtubule targeted agent; and (e) ionising radiation.
Owner:CANCER RES TECH LTD

Compositions and methods for treating pterygium

ActiveUS9980901B2Stabilization of pterygium sizeStabilizing pterygiumOrganic active ingredientsSenses disorderPurine AntimetaboliteSurgery
Compositions and methods for inducing pterygium regression from visual axis / central cornea, stabilizing pterygium, treating hyperemia and symptoms in pterygium patients, and treating pterygium recurrence following pterygiectomy are disclosed. The methods include administration of a multikinase inhibitor, an antimetabolite or a combination thereof to patients in need thereof.
Owner:CLOUDBREAK THERAPEUTICS LLC

Bicyclylaryl-aryl-amine compounds and their use

The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain bicyclylaryl-aryl-amines compounds of the following formula (referred to herein as BCAA compounds), which, inter alia, inhibit Checkpoint Kinase 1 (CHK1) kinase function. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit CHK1 kinase function, and in the treatment of diseases and conditions that are mediated by CHK1, that are ameliorated by the inhibition of CHK1 kinase function, etc., including proliferative conditions such as cancer, etc., optionally in combination with another agent, for example, (a) a DNA topoisomerase I or II inhibitor; (b) a DNA damaging agent; (c) an antimetabolite or TS inhibitor; (d) a microtubule targeted agent; and (e) ionising radiation:
Owner:CANCER RES TECH LTD

Slow released anticancer injection with both antimetabolite and its synergist

The slow released anticancer injection consists of slow released microsphere and solvent. The slow released microsphere includes effective anticancer component and slow releasing supplementary material, and the solvent is special solvent containing suspending agent. The effective anticancer component is antimetabolite Zalcitabine, Emtricitabine, etc and / or antimetabolite synergist selected from hormone anticarcinogen and / or platinum compound. The slow releasing supplementary material is selected from difatty acid-sebacic acid copolymer, poly (erucic acid dipolymer-sebacic acid), poly(fumaric acid-sebacic acid), etc or their composition. The suspending agent is carboxymethyl cellulose, etc. and has viscosity of 80-3000 cp at 20-30 deg.c. The slow released microsphere may be also prepared into slow released implanting agent for use alone or together with chemotherapeutic medicine, radiotherapeutic medicine, etc.
Owner:DASEN BIOLOGICAL PHARMA CO LTD

5-[[4-[[morpholin-2-yl]methylamino]-5-(trifluoromethyl)-2-pyridyl]amino]pyrazine-2-carbonitrile and therapeutic uses thereof

ActiveUS20150126471A1Increased endogenous replicative stressIncreased endogenous activationBiocideOrganic chemistryDiseasePyrazine
The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to 5-[[4-[[morpholin-2-yl]methylamino]-5-(trifluoromethyl)-2-pyridyl]amino]pyrazine-2-carbonitrile compounds (referred to herein as “TFM compounds”) which, inter alia, inhibit Checkpoint Kinase 1 (CHK1) kinase function. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit CHK1 kinase function, and in the treatment of diseases and conditions that are mediated by CHK1, that are ameliorated by the inhibition of CHK1 kinase function, etc., including proliferative conditions such as cancer, etc., optionally in combination with another agent, for example, (a) a DNA topoisomerase I or II inhibitor; (b) a DNA damaging agent; (c) an antimetabolite or a thymidylate synthase (TS) inhibitor; (d) a microtubule targeted agent; (e) ionising radiation; (f) an inhibitor of a mitosis regulator or a mitotic checkpoint regulator; (g) an inhibitor of a DNA damage signal transducer; or (h) an inhibitor of a DNA damage repair enzyme.
Owner:CANCER RES TECH LTD

9H-pyrimido[4,5-B]indoles, 9H-pyrido[4',3':4,5]pyrrolo[2,3-D]pyridines, and 9H 1,3,6,9 tetraaza-fluorenes as CHK1 kinase function inhibitors

The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain tricyclic compounds (referred to herein as TC compounds), and especially certain 9H-pyrimido[4,5-b]indole, 9H-pyrido[4′,3′:4,5]pyrrolo[2,3-d]pyridine, and 9H-1,3,6,9-tetraaza-fluorene compounds, which, inter alia, inhibit Checkpoint Kinase 1 (CHK1) kinase function. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit CHK1 kinase function, and in the treatment of diseases and conditions that are mediated by CHK1, that are ameliorated by the inhibition of CHK1 kinase function, etc., including proliferative conditions such as cancer, etc., optionally in combination with another agent, for example, (a) a DNA topoisomerase I or II inhibitor; (b) a DNA damaging agent; (c) an antimetabolite or TS inhibitor; (d) a microtubule targeted agent; and (e) ionising radiation.
Owner:CANCER RES TECH LTD

Therapeutic agents for pancreatic cancer

We achieved the present invention on the basis of the finding that an excellent therapeutic effect against pancreatic cancer can be obtained by administering an IL-6 inhibitor and an antimetabolite to pancreatic cancer patients. We also found that metastatic lesions from human pancreatic cancer can be reduced and ascites can be eliminated.
Owner:NAT CANCER CENT +1

Anticancer medicine composition containing antimetabolite

The anticancer medicine composition connecting antimetabolite includes effective anticancer component and medicinal supplementary material, and features the effective anticancer component, which includes antimetabolite and antimetabolite synergist selected from bichlorethamm medicine, taxol anticarcinogen, and tetrazine. The medicinal supplementary material is mainly biocompatible and degradable absorptive polymer. The anticancer medicine composition is mainly slow released implantation preparation or slow released injection. The slow released injection consists of slow released microballoon and solvent. Implanting or injecting the slow released preparation to local tumor part can lower the systematic toxic reaction of the medicine and raise the medicine concentration of local tumor part selectively to raise the treating effect.
Owner:JINAN SHUAIHUA PHARMA TECH

Combination of EPA, DPA and/or DHA with a chemotherapeutic agent

The present invention refers to a combination of an eicosapentaenoic acid (EPA), docosapentaenoic acid (DPA), and / or docosahexanoic acid (DHA), or a combination of a nutritional composition comprising EPA, DPA, and / or DHA and a protein, a carbohydrate, a fat, an amino acid, a fatty acid, a dietary fibre, a vitamin, a mineral, a trace element, ß-carotenoid, a flavonoid, a nucleotide, L- carnitin, choline, inositol, taurine, creatine, and / or a co-enzyme, wherein EPA is in an amount of 1 to 1000 mg / 100ml, preferably 100 to 700 mg / 100ml, DPA is in an amount of >50 mg / 100ml, preferably 50 to 1000 mg / 100ml, preferably 6 to 800 mg / 100ml, more preferably 80 to 500 mg / 100ml and / or DHA is in an amount of 1 to 500 mg / 100ml, preferably 1 to 300 mg / 100ml and a chemotherapeutic agent selected from the group consisting of an alkylating drug, an antimetabolite, an antimytotic cytostatic, a topoisomerase inhibitor, antitumor antibiotic, and any other cytostatic, and / or a radiotherapy. These combinations are successful for use in treating a neoplastic disease like the method for treating a neoplastic disease comprising EPA, DPA, and / or DHA or a nutritional composition comprising EPA, DPA, and / or DHA and and a protein, a carbohydrate, a fat, an amino acid, a fatty acid, a dietary fibre, a vitamin, a mineral, a trace element, ß-carotenoid, a flavonoid, a nucleotide, L- carnitin, choline, inositol, taurine, creatine, and / or a co-enzyme in combination with a chemotherapeutic agent, and / or radiotherapy.
Owner:NV NUTRICIA

Method for decreasing inflammation and stress in a mammal using glucose antimetaboltes, avocado or avocado extracts

The present invention is directed to a method for decreasing inflammation and stress in a mammal comprising; administration to a mammal a composition comprising a glucose antimetabolite; and wherein said composition comprises amounts of the glucose anti-metabolite sufficient to lower a level of a C-reactive protein in the blood of the mammal subsequent to administration of the glucose anti-metabolite.
Owner:IAMS

Agents for intravitreal administration to treat or prevent disorders of the eye

Methods and preparations for treating disorders of the eye and / or causing posterior vitreous disconnection or disinsertion. Preparations containing (a) urea, (b) urea derivatives (e.g., hydroxyurea, thiourea), (c) a non-steroidal anti-inflamatory agent, (d) antimetabolites, (e) urea, urea derivatives, non-enzymatic proteins, nucleosides, nucleotides and their derivatives (e.g., adenine, adenosine, cytosine, cytadine, guanine, guanitadine, guanidinium, thymidine, thimitadine, uradine, uracil, cystine), uric acid, calcium acetal salicylate, ammonium sulfate or other compound capable of causing non-enzymatic dissolution of the hyaloid membrane or (e) any of the possible combinations thereof, are administered to the eye in therapeutically effective amounts.
Owner:透明视网膜技术公司

Combination of an HDAC inhibitor and an antimetabolite

The invention relates to a combination which comprises:(a) a HDAI; and(b) an anti-metabolite,for simultaneous, concurrent, separate or sequential use, especially for use in the treatment of proliferative diseases, more specifically MDS or AML. The invention also relates to pharmaceutical compositions comprising such a combination and to a method of treating MDS or AML, in a mammal, particularly a human, with such a combination. The present invention further also relates to a commercial package or product comprising such a combination.
Owner:NOVARTIS AG

Gemcitabine-containing anti-cancer medicine sustained-release injection

The invention relates to cancer therapy drug sustained-release injection containing gemcitabine. The injection comprises sustained-release microspheres and dissolvent, wherein, the sustained-release microspheres comprise active ingredients for cancer therapy and sustained-release auxiliary materials, and the dissolvent is special dissolvent containing suspending agent. The active ingredients for cancer therapy comprise antimetabolite of gemcitabine or antimetabolite selected from zalcitabine, emtritabine, galocitabine, ibacitabine, ancitabine, decitabine, flurocitabine, enocitabine, imidazoletabine, capecitabine, gemcitabine, fludarabine or cladribine, and / or antimetabolite synergist selected from phosphoinositide 3-kinase inhibitor, pyrimidine analogs and / or DNA repair enzyme inhibitor; the sustained-release auxiliary materials comprise polifeprosan, bi-fatty acid, decanedioic copolymer, polylactic copolymer and EVAc; the viscocity of the suspending agent is 100cp to 3000cp (at 20 to 30 DEG C) and the suspending agent is selected from sodium carboxymethyl cellulose. The sustained-release microspheres can also be produced into sustained-release implant, and by injecting or positioning the sustained release agent in tumor or tumor margin, the efficacy of non-operative treatment such as radiation treatment and chemical treatment can be enhanced.
Owner:SHANDONG LANJIN PHARMA +1

Agents for intravitreal administration to treat or prevent disorders of the eye

Methods and preparations for treating disorders of the eye and / or causing posterior vitreous disconnection or disinsertion. Preparations containing (a) urea, (b) urea derivatives (e.g., hydroxyurea, thiourea), (c) a non-steroidal anti-inflamatory agent, (d) antimetabolites, (e) urea, urea derivatives, non-enzymatic proteins, nucleosides, nucleotides and their derivatives (e.g., adenine, adenosine, cytosine, cytadine, guanine, guanitadine, guanidinium, thymidine, thimitadine, uradine, uracil, cystine), uric acid, calcium acetal salicylate, ammonium sulfate or other compound capable of causing non-enzymatic dissolution of the hyaloid membrane or (e) any of the possible combinations thereof, are administered to the eye in therapeutically effective amounts.
Owner:透明视网膜技术公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products